Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia

American Journal of Hematology

Volumn 92, Issue 9, 2017, Pages 845-850

  Ragon, Brittany Knick ^a   Daver, Naval ^a   Garcia Manero, Guillermo ^a   Ravandi, Farhad ^a   Cortes, Jorge ^a   Kadia, Tapan ^a   Oran, Betul ^a   Ohanian, Maro ^a   Ferrajoli, Alessandra ^a   Pemmaraju, Naveen ^a   Kantarjian, Hagop M ^a   Borthakur, Gautam ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CD135 ANTIGEN; CLOFARABINE; CYTARABINE; DECITABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NUCLEOPHOSMIN; PROTEIN P53; STEM CELL FACTOR; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; GEMTUZUMAB; MONOCLONAL ANTIBODY; VIDARABINE;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONSOLIDATION CHEMOTHERAPY; CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; REPEATED DRUG DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALVAGE THERAPY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CHROMOSOME 21; CHROMOSOME 8; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE TRANSLOCATION; GENETIC EPIGENESIS; GENETICS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADULT; AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; DISEASE-FREE SURVIVAL; EPIGENESIS, GENETIC; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; SURVIVAL RATE; TRANSLOCATION, GENETIC; VIDARABINE;

EID: 85020460570     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24782     Document Type: Article

References (32)

1. Bhatt VR, Kantarjian H, Cortes JE, Ravandi F, Borthakur G. Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. Clin Lymphoma Myeloma Leukemia. 2013;13(2):10–1016. /j.clml.2012.11.006.
2. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58(18):4173–4179.
3. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12):3767–3775.
4. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006;135(2):165–173.
5. Yin JAL, O'brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120(14):2826–2835.
6. Martinelli G, Rondoni M, Buonamici S, et al. Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely. Haematologica. 2004;89(4):495–497.
7. Krauter J, Görlich K, Ottmann O, et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol. 2003;21(23):4413–4422.
8. Corbacioglu A, Scholl C, Schlenk RF, et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol. 2010;28(23):3724–3729.
9. Tobal K, Newton J, Macheta M, et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood. 2000;95(3):815–819.
10. Buonamici S, Ottaviani E, Testoni N, et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood. 2002;99(2):443–449.
11. Leroy H, de Botton S, Grardel-Duflos N, et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia. 2005;19(3):367–372.
12. Stentoft J, Hokland P, Østergaard M, Hasle H, Nyvold CG. Minimal residual core binding factor AMLs by real time quantitative PCR—Initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res. 2006;30(4):389–395.
13. Perea G, Lasa A, Aventin A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia. 2005;20(1):87–94.
14. Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121(12):2213–2223.
15. Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965–970.
16. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a cancer and leukemia group B study. J Clin Oncol. 2006;24(24):3904–3911.
17. Boissel N, Renneville A, Leguay T, et al. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French acute myeloid leukemia intergroup trial. Haematologica. 2015;100(6):780–785.
18. Agrawal S, Unterberg M, Koschmieder S, et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res. 2007;67(3):1370–1377.
19. Kroeger H, Jelinek J, Estécio MRH, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 2008;112(4):1366–1373.
20. Suzuki R, Onizuka M, Kojima M, et al. Preferential hypermethylation of the Dickkopf-1 promoter in core-binding factor leukaemia. Br J Haematol. 2007;138(5):624–631.
21. Cheng CK, Li L, Cheng SH, et al. Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia. Blood. 2011;118(25):6638–6648.
22. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21(1):103–107.
23. Liu S, Shen T, Huynh L, et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res. 2005;65(4):1277–1284.
24. Blum W, Sanford BL, Klisovic R, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia. 2017;31(1):34–39.
25. Boumber Y, Kantarjian H, Jorgensen J, et al. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012;26(11):2428–2431.
26. Beillard E, Pallisgaard N, van der Velden VHJ, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using/‘real-time/’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia. 2003;17(12):2474–2486.
27. Gabert J, Beillard E, van der Velden VHJ, et al. Standardization and quality control studies of/‘real-time/’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer Program. Leukemia. 2003;17(12):2318–2357.
28. Borthakur G, Cortes JE, Estey EE, et al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014;89(10):964–968.
29. Chen W, Jones D, Jeffrey Medeiros L, Luthra R, Lin P. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. Br J Haematol. 2005;130(5):726–728.
30. Kadia TM, Ravandi F, Cortes J, Kantarjian H. Toward individualized therapy in acute myeloid leukemia: a contemporary review. JAMA Oncol. 2015;1(6):820–8
31. Paschka P, Du J, Schlenk RF, et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood. 2013;121(1):170–177.
32. Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, et al. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia. Leukemia. 2016;30(3):708–715.